

Please type a plus sign (+) inside this box →

0

01-29-01

A

PTO/SB/05 (08-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b>  <i>(Only for new nonprovisional applications under 37 CFR 1.53 (b))</i>		Attorney Docket No.	LEX-0122-USA
		First Inventor	C. Alexander Turner Jr. et al.
		Title	Novel Human Neurexin-Like Proteins and Polynucleotides Encoding the Same
		Express Mail label No.	EL 747 066 936 US

<b>APPLICATION ELEMENTS</b> <i>See MPEP chapter 600 concerning utility patent application contents.</i>	<b>ADDRESS TO:</b> Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
--	---

1. <input type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original and a duplicate for fee processing)</i> 2. <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. 3. <input checked="" type="checkbox"/> Specification [Total Pages 28] <i>(preferred arrangement set forth below)</i> - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the invention - Brief Summary of the invention - Brief Description of the drawings (if filed) - Detailed Description - Claim(s) - Abstract of the disclosure 4. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets 3] 5. Oath or Declaration [Total Pages 3] a. <input checked="" type="checkbox"/> unexecuted (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 17 completed)</i> i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b) 6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76	7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i> a. <input type="checkbox"/> Computer Readable Form (CRF) b. Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or i.i. <input checked="" type="checkbox"/> paper c. <input type="checkbox"/> Statements verifying identity of above copies
--	--

<b>ACCOMPANYING APPLICATION PARTS</b>	
9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))	
10. <input type="checkbox"/> 37 CFR 3.73(b) Statement (when there is an assignee)	<input checked="" type="checkbox"/> Power of Attorney
11. <input type="checkbox"/> English Translation Document (if applicable)	
12. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449	<input type="checkbox"/> Copies of IDS Citations
13. <input type="checkbox"/> Preliminary Amendment	
14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)	
15. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)	
16. <input type="checkbox"/> Other	

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

<input type="checkbox"/> Continuation	<input type="checkbox"/> Divisional	<input type="checkbox"/> Continuation-in-part (CIP)	of prior application No.:
Prior application information: Examiner		Group/Art Unit:	
For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.			

**18. CORRESPONDENCE ADDRESS**

☒ Customer Number or Bar Code Label (Insert Customer Number or bar code label here) or ☐ Correspondence address below

Name	24231		
Address	PATENT TRADEMARK OFFICE		
City	State	Zip	
Country	Telephone	Fax	

Name (Print/Type)	Lance K. Ishimoto	Registration No. (Attorney/Agent)	41866
Signature	<i>Lance K. Ishimoto</i>	Date	January 26, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

**PCT (ANNEX - FEE CALCULATION SHEET)**

LEX-0122-PCT

Original (for **SUBMISSION**) - printed on 26.01.2001 10:49:18 AM


(This sheet is not part of and does not count as a sheet of the international application)

<b>0</b>	<b>For receiving Office use only</b>	
0-1	International Application No.	
0-2	Date stamp of the receiving Office	
<b>0-4</b>	<b>Form - PCT/RO/101 (Annex)</b>	
0-4-1	PCT Fee Calculation Sheet Prepared using	<b>PCT-EASY Version 2.91 (updated 01.01.2001)</b>
0-9	Applicant's or agent's file reference	<b>LEX-0122-PCT</b>
<b>2</b>	<b>Applicant</b>	<b>LEXICON GENETICS INCORPORATED</b>
<b>12</b>	<b>Calculation of prescribed fees</b>	
12-1	Transmittal fee T	⇒ 240
12-2	Search fee S	⇒ 846
12-3	International fee	
	Basic fee (first 30 sheets) b1	382
12-4	Remaining sheets	40
12-5	Additional amount (X)	9
12-6	Total additional amount b2	360
12-7	b1 + b2 = B	742
12-8	Designation fees	
	Number of designations contained in international application	86
12-9	Number of designation fees payable (maximum 6)	6
12-10	Amount of designation fee (X)	82
12-11	Total designation fees D	492
12-12	PCT-EASY fee reduction R	-117
12-13	Total International fee (B+D-R) I	⇒ 1,117
12-14	Fee for priority document	
	Number of priority documents requested	2
12-15	Fee per document (X)	15
12-16	Total priority document fee P	⇒ 30
<b>12-17</b>	<b>TOTAL FEES PAYABLE (T+S+I+P)</b>	⇒ <b>2,233</b>
<b>12-19</b>	<b>Mode of payment</b>	<b>authorization to charge deposit account</b>
<b>12-20</b>	<b>Deposit account instructions</b>	
	The receiving Office:	<b>United States Patent and Trademark Office (USPTO) (RO/US)</b>
12-20-1	is hereby authorized to charge the total fees indicated above to my deposit account	✓
12-20-2	is hereby authorized to charge any deficiency or credit any over-payment in the total fees indicated above to my deposit account	✓

## PCT (ANNEX - FEE CALCULATION SHEET)

LEX-0122-PCT

Original (for SUBMISSION) - printed on 26.01.2001 10:49:18 AM

12-20-3	is hereby authorized to charge the fee for preparation and transmittal of the priority document to the International Bureau of WIPO to my deposit account	✓	JCS03 U.S. PTO 09/770643 01/26/01
12-21	Deposit account No.	50-0892	
12-22	Date	26 January 2001 (26.01.2001)	
12-23	Name and signature	ISHIMOTO, Lance, K. <i>Reg No. 41,866</i> 	

## VALIDATION LOG AND REMARKS

13-2-2	Validation messages States	Green? More designations could be made. The following States have not been designated: US. Please verify.
13-2-6	Validation messages Contents	Green? The international application contains no drawings. Please verify.
13-2-8	Validation messages Payment	Green? Please ensure that you have a valid deposit account with the receiving Office selected.



24231

PATENT TRADEMARK OFFICE

IN THE PATENT COOPERATION TREATY

Applicant: LEXICON GENETICS INCORPORATED



Int'l. Appl. No.: to be assigned

Attorney Docket No.: LEX-0122-PCT

Int'l. Filing Date: January 26, 2001

For: NOVEL HUMAN NUEREXIN-LIKE  
PROTEINS AND  
POLYNUCLEOTIDES ENCODING  
THE SAME

**VERIFIED STATEMENT**

BOX PCT  
Asst. Commission for Patents  
Washington, D.C. 20231

Attn: RO/US  
Sir:

I, DRENDA D. THOMAS, do declare and state as follows:

1. I prepared a Sequence Listing in paper and computer readable form in connection with the above-captioned patent application, both of which are being submitted herewith.
2. I hereby state that the contents of the paper and computer readable copies of the Sequence Listing are the same.

Signed

1/26/01  
Date

Drenda Thomas  
Drenda D. Thomas